Clinical

Treatment Tolerability in Patients with Immunoglobulin Light-Chain Amyloidosis

Avery A. Rizio, PhD, Michelle K. White, PhD, Kristen L. McCausland, MPH, PhD, Tiffany P. Quock, MS, PhD, Spencer D. Guthrie, MS, MBA, MPH, Miyo Yokota, PhD, Martha S. Bayliss, MS, MSc

Avery A. Rizio, PhD; Michelle K. White, PhD; Kristen L. McCausland, MPH, PhD; Tiffany P. Quock, MS, PhD; Spencer D. Guthrie, MS, MBA, MPH; Miyo Yokota, PhD; Martha S. Bayliss, MS, MSc

Clinical, Original Research

Analysis of Real-World Dosing Patterns for the 3 FDA-Approved Medications in the Treatment of Fibromyalgia

Craig White, PhD, Winghan Jacqueline Kwong, PharmD, PhD, Hilary Armstrong, PhD, Michael Behling, Jeffrey Niemira, Kathy Lang, PhD

Craig White, PhD; Winghan Jacqueline Kwong, PharmD, PhD; Hilary Armstrong, PhD; Michael Behling; Jeffrey Niemira; Kathy Lang, PhD

Stakeholder Perspective

Real-World Drug Prescribing and Utilization Studies Can Inform Optimized Patient Care and Insurance Coverage

F. Randy Vogenberg, PhD, RPh

by F. Randy Vogenberg, PhD, FASHP

Clinical, Original Research

Assessing the Level of Patient-Specific Treatment Recommendations in Clinical Practice Guidelines for Hemodialysis Vascular Access in the United States

Gilbert L. Queeley, PhD, Ellen S. Campbell, PhD, Askal A. Ali, PhD

Gilbert L. Queeley, PhD; Ellen S. Campbell, PhD; Askal A. Ali, PhD

Stakeholder Perspective

The Challenge of Maintaining Vascular Access in Patients with End-Stage Renal Disease

Raymond L. Singer, MD, MMM, CPE

by Raymond L. Singer, MD, MMM, CPE

Clinical, Original Research

Prior Authorization for Elective Diagnostic Catheterization: The Value of Reviewers in Cases with Clinical Ambiguity

Adam C. Powell, PhD, Stephen E. Price, DPT, MBA, Khoa Nguyen, MS, Gary L. Smith, MS, James W. Long, BSBA, Uday U. Deshmukh, MD, MPH

Adam C. Powell, PhD; Stephen E. Price, DPT, MBA; Khoa Nguyen, MS; Gary L. Smith, MS; James W. Long, BSBA; Uday U. Deshmukh, MD, MPH

Stakeholder Perspective

Standardized Documentation Can Improve Diagnostic Testing Decisions for Patients with Cardiovascular Disease

Raymond L. Singer, MD, MMM, CPE, FACS

by Raymond L. Singer, MD, MMM, CPE

Clinical, Original Research

Long-Term Outcomes of a Cardiovascular and Diabetes Risk-Reduction Program Initiated by a Self-Insured Employer

Nicole D. White, PharmD, CDE, Thomas L. Lenz, PharmD, FACLM, Maryann Z. Skrabal, PharmD, CDE, Jessica J. Skradski, PharmD, Louis Lipari, PharmD candidate

Nicole D. White, PharmD, CDE; Thomas L. Lenz, PharmD, FACLM; Maryann Z. Skrabal, PharmD, CDE; Jessica J. Skradski, PharmD; Louis Lipari, PharmD candidate

Stakeholder Perspective

Influencing Patient Outcomes Through Enhanced Multidisease-Focused Interventions

Jack E. Fincham, PhD, RPh

by Jack E. Fincham, PhD, RPh

Clinical, Original Research

Comparing Treatment Modalities for End-Stage Renal Disease: A Meta-Analysis

Gilbert L. Queeley, PhD, Ellen S. Campbell, PhD

Gilbert L. Queeley, PhD, and Ellen S. Campbell, PhD

Stakeholder Perspective

Dialysis Procedures and Health-Related Quality of Life: The Challenge of Creating Evidence-Based Healthcare in End-Stage Renal Disease

Michael F. Murphy, MD, PhD

by Michael F. Murphy, MD, PhD

Clinical, Original Research

Delayed Treatment Acceleration in Patients with Rheumatoid Arthritis Who Have Inadequate Response to Initial Tumor Necrosis Factor Inhibitors: Data from the Corrona Registry

Dimitrios A. Pappas, MD, Robert A. Gerber, PharmD, MA, MBA, Heather J. Litman, PhD, David Gruben, PhD, Jamie Geier, PhD, Winnie D. Hua, MS, Connie Chen, PharmD, Youfu Li, MD, MPH, Joel M. Kremer, MD, John S. Andrews, MD, Jeffrey A. Bourret, PharmD

Dimitrios A. Pappas, MD; Robert A. Gerber, PharmD; Heather J. Litman, PhD; David Gruben, PhD; Jamie Geier, PhD; Winnie D. Hua, MS; Connie Chen, PharmD; Youfu Li, MD, MPH; Joel M. Kremer, MD; John S. Andrews, MD; Jeffrey A. Bourret, PharmD

Stakeholder Perspective

Limited Guidelines and Treatment Success in the Current Standard of Care for Patients with Rheumatoid Arthritis Provide an Opportunity to Inform New Treatment Protocols

Gary Branning, MBA

by Gary Branning, MBA

Clinical, Original Research

Patient Preferences and Therapeutic Satisfaction with Topical Agents for Rosacea: A Survey-Based Study

Todd Williamson, PhD, MSc, Wendy Y. Cheng, MPhil, MPH, Nora McCormick, MSc, Francis Vekeman, MA

Todd Williamson, PhD, MSc; Wendy Y. Cheng, MPhil, MPH; Nora McCormick, MSc; Francis Vekeman, MA

Stakeholder Perspective

There’s Room for Improvement in Rosacea Treatment

Gary M. Owens, MD

by Gary M. Owens, MD

Clinical

Predictors of Transitioning to Incident Chronic Opioid Therapy Among Working-Age Adults in the United States

J. Douglas Thornton, PharmD, PhD, Nilanjana Dwibedi, BPharm, MBA, PhD, Virginia Scott, PhD, Charles D. Ponte, PharmD, Douglas Ziedonis, MD, Nethra Sambamoorthi, PhD, Usha Sambamoorthi, PhD

J. Douglas Thornton, PharmD, PhD; Nilanjana Dwibedi, PhD; Virginia Scott, PhD; Charles D. Ponte, PharmD; Douglas Ziedonis, MD; Nethra Sambamoorthi, PhD; Usha Sambamoorthi, PhD

Stakeholder Perspective

Addiction Prediction: Preventing Iatrogenic Opioid Dependence

Albert Tzeel, MD, MHSA, CPE, FAAPL

by Albert Tzeel, MD, MHSA, CPE, FAAPL

Clinical

Newly Diagnosed Hepatitis C in the US Commercially Insured Population Before and After the 2012 Implementation of Expanded Screening Guidelines

Bruce S. Pyenson, FSA, MAAA, Gabriela Dieguez, FSA, MAAA, Christine Ferro, CHFP, Maushumi Mavinkurve, MPH, Yuri Sanchez Gonzalez, PhD

Bruce S. Pyenson, FSA, MAAA; Gabriela Dieguez, FSA, MAAA; Christine Ferro; Maushumi Mavinkurve, MPH; Yuri Sanchez Gonzalez, PhD

Stakeholder Perspective

Importance of Health Outcomes Research for the Treatment of Hepatitis C Infection

Jack E. Fincham, PhD, RPh

by Jack E. Fincham, PhD, RPh

Page 3 of 14
Results 21 - 30 of 135